IBM Digs Deeper Roots In Medtech, As AdvaMed Builds Digital Footprint
Executive Summary
IBM is getting more heavily invested in the medical device industry, announcing two major partnerships this week with diagnostic-maker Illumina and US FDA. The move is part of a larger industry trend of tech firms becoming more active in the medtech sector, and AdvaMed is adjusting to the new context.
You may also be interested in...
2018 An Inflection Point For mHealth After An Active Year
The past year saw US FDA and industry work hard and fast to prepare for what looks like an inevitable boom in the digital-health sector. According to interviews, the time is ripe for adoption of mobile health apps to help reduce health-care costs, but the brave new world also brings with it big challenges.
Podcast: Nadim Yared Hits The Ground Running As AdvaMed Chair
In a podcast interview to discuss his initial experience as chairman of AdvaMed, CVRx CEO Nadim Yared talks about the group's laser focus on device-tax repeal, irrespective of broader GOP health-care debates and controversy, its capacity to handle unpredictability and change in Washington, DC, and more.
With Gottlieb Sworn In, His Focus Should Be On Quick User-Fee Passage, Industry Advocates Say
Scott Gottlieb was sworn in as US FDA commissioner May 11. Device-industry lobbyists say championing quick passage of user-fee reauthorization should be his near-term priority. Gottlieb is a well-known figure by some in industry, including AdvaMed chief Scott Whitaker, who served with him at HHS during the George W. Bush Administration.